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Background: This study was performed to develop a validated score predicting ambulatory status after
radiotherapy (RT) alone for metastatic spinal cord compression (MSCC) in elderly patients.
Methods: 1,129 elderly patients (≥65 years) were assigned to the test (N = 565) or validation group (N = 564). In the
test group, nine pre-treatment factors (age, gender, tumor type, number of involved vertebrae, pre-RT ambulatory
status, other bone metastases, visceral metastases, interval cancer diagnosis to RT, time developing motor deficits)
and fractionation regimen were investigated. Factors significantly associated with post-RT ambulatory status on
multivariate analysis were included in the score. The score for each factor was determined by dividing the post-RT
ambulatory rate at 1 month (%) by 10. The total score represented the sum of these scores.
Results: In the multivariate analysis of the test group, age, primary tumor type, pre-RT ambulatory status, visceral
metastases, and time developing motor deficits were significantly associated with post-RT ambulatory status. Total
scores were 19 to 41 points. In the test group, post-RT ambulatory rates were 5% for 19-25 points, 35% for 26-30
points, 80% for 31-34 points, and 98% for 35-41 points (p < 0.001). 6-month survival rates were 11%, 21%, 59% and
76%, respectively. In the validation group, post-RT ambulatory rates were 4%, 33%, 77% and 98%, respectively
(p < 0.001).
Conclusions: Patients achieving 19-25 points had very poor functional outcomes and survival, and may receive
single-fraction RT for pain relief. Selected patients with 26-34 points may benefit from additional surgery. Patients
achieving ≥35 points achieved favorable results after RT alone.
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Personalized treatment has been studied more during
recent years, particularly in palliative situations such as
metastatic spinal cord compression (MSCC). Radiotherapy
(RT) alone is the most commonly administered treatment
for MSCC world wide. Maintaining or regaining ambula-
tory function is very important for patients developing
MSCC. A randomized trial has suggested that selected
patients benefit from upfront decompressive surgery
in addition to RT in terms of higher post-treatment
ambulatory rates when compared to RT alone [1]. However,* Correspondence: rades.dirk@gmx.net
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unless otherwise stated.many patients, particularly elderly patients, may not be able
to withstand a neurosurgical intervention, which is asso-
ciated with a rate of major complications of >10% even in
younger patients [1-4]. Therefore, it appears reasonable to
develop an instrument that allows the estimation of the
ambulatory status after RT alone in order to better identify
patients who benefit from upfront surgery and those who
may not need it.
This study was initiated in order to develop a validated
tool that helps predict the probability of being ambula-
tory after RT alone specifically for elderly patients
(65 years or older). Elderly patients should be regarded a
separate group of patients. The course of their disease
and the ability to tolerate aggressive treatments such astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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patients.
Methods
A total of 1,129 elderly (age ≥65 years) patients treated
with RT alone for MSCC between 1995 and 2010 were
included in this retrospective study. In this study, “eld-
erly” has been defined according to the homepage of the
world health organization (WHO), where it is stated that
“most developed world countries have accepted the
chronological age of 65 years as a definition of 'elderly'
or older person” [5]. In addition, Orimo et al. reported that
conventionally, “elderly” has been defined as a chrono-
logical age of 65 years old or older, while those from 65
through 74 years old are referred to as “early elderly” and
those over 75 years old as “late elderly” [6].
Further inclusion criteria included motor deficits of
the lower extremities caused by MSCC, no prior treat-
ment to the involved parts of the spinal cord, and admin-
istration of corticosteroids. The data were obtained from
the patients themselves, their treating physicians, and the
patients’ hospital charts. The study has been approved by
the ethics committee of the University of Lübeck. The
treatment volumes encompassed one normal vertebra
above and below the involved vertebrae. Of the entire
cohort, 169 patients (14%) had multi-level involvement by
MSCC resulting in more than one treatment volume.
Prior to RT the patients were generally presented to a
surgeon to discuss the option of decompressive surgery.
Patients with MSCC due to vertebral fracture with bony
impingement of the spinal cord or nerve roots were not
included in this study, since these patients were clear
candidates for surgery. In this study patients, who received
1×8 Gy were also included, since several studies have
demonstrated that 1×8 Gy is similarly effective compared
to fractionated regimens with respect to improvement of
motor function and ambulatory status [7-9].
The patients were randomly assigned to the test group
(N = 565) or the validation group (N = 564). Patient char-
acteristics were not significantly different between these
groups as demonstrated in Table 1. The comparisons of
both groups with respect to the distribution of the patient
characteristics were performed using the Chi-square test.
In the test group, nine potential prognostic factors were
investigated including age (65-70 vs. 71-80 vs. ≥81 years),
gender, primary tumor (breast cancer vs. prostate cancer
vs. myeloma/lymphoma vs. lung cancer vs. cancer of
unknown primary vs. renal cell carcinoma vs. colorectal
cancer vs. other tumors), number of involved vertebrae
(1-2 vs. 3-4 vs. ≥5), ambulatory status prior to RT (not
ambulatory vs. ambulatory), other bone metastases prior
to RT (no vs. yes), visceral metastases (extra-spinal non-
osseous metastases) prior to RT (no vs. yes), interval
between first diagnosis of cancer and RT of MSCC(≤15 vs. >15 months), and time of developing motor
deficits prior to RT (1-7 vs. 8-14 vs. >14 days). In
addition to these pre-treatment factors, the fractionation
regimen has been evaluated (1×8 Gy vs. 5×4 Gy vs. 10×3
Gy vs. 15×2.5 Gy vs. 20×2 Gy). The ECOG performance
status was not analyzed, since it was directly related to the
pre-treatment ambulatory status. The vast majority of am-
bulatory patients have ECOG-PS 2, and patients who are
not ambulatory have ECOG-PS 3 or 4. In the test group,
252 patients (45%) had ECOG-PS 2, 273 patients (48%)
had ECOG-PS 3 and 40 patients (7%) had ECOG-PS 4. In
the validation group, 258 patients (46%) had ECOG-PS 2,
271 patients (48%) had ECOG-PS 3 and 35 patients (6%)
had ECOG-PS 4.
The potential prognostic factors have been included in
a multivariate analysis performed with a logistic regression
and the backward stepwise (likelihood ratio) method. The
prognostic factors that were significant in the multivariate
analysis of the test group were included in the score. The
score for each significant factor was obtained by dividing
the post-treatment (i.e. 1 month following RT) ambulatory
rate (given in%) by 10. The total score represented the
sum of the scores for each significant factor. Based on the
total scores, four prognostic groups were formed. In order
to test the reproducibility of the score, each of the four
prognostic groups of the test group was compared to the
corresponding prognostic group of the validation group
with the Chi-square test.
Results
In the multivariate analysis of the test group, ambulatory
status at 1 month following RT was significantly associ-
ated with age (p = 0.004), visceral metastases (p = 0.017),
type of primary tumor (p = 0.002), time developing motor
deficits prior to RT (p < 0.001), and pre-RT ambulatory
status (p < 0.001). The post-RT ambulatory rates related to
the potential prognostic factors, the p-values obtained
from the multivariate analysis of the test group, and the
corresponding score for each of the five significant prog-
nostic factors are given in Table 2. Total scores ranged
from 19 to 41 points (Figure 1).
Based on the total scores, the patients were assigned
to four prognostic groups, 19-25 points (group A, n = 106),
26-30 points (group B, n = 110), 31-34 points (group C,
n = 99), and 35-41 points (group D, n = 250). The ambu-
latory rates at 1 month following RT were 5%, 35%, 80%
and 98%, respectively (p < 0.001, Chi-square test). In
group D, the post-RT ambulatory rates were 99% (228/
231) at 3 months, 99% (195/196) at 6 months, and 79%
(15/19) at 12 months following RT. The 6-month survival
rates were 11% in group A, 21% in group B, 59% in group
C, and 76% in group D, respectively.
In the validation group, the ambulatory rates at 1 month
following RT were 4% in group A, 33% in group B, 77% in








65-70 years 230 (41) 217 (39)
71-80 years 266 (47) 283 (50)
≥ 81 years 69 (12) 64 (11)
Gender 0.89
Female 197 (35) 201 (36)
Male 368 (65) 363 (64)
Type of primary tumor 0.91
Breast cancer 89 (16) 106 (19)
Prostate cancer 150 (27) 159 (28)
Myeloma/lymphoma 51 (9) 50 (9)
Lung cancer 112 (20) 108 (19)
Cancer of unknown
primary
44 (8) 45 (8)
Renal cell carcinoma 34 (6) 32 (6)
Colorectal cancer 28 (5) 25 (4)




1-2 235 (42) 219 (39)
3-4 191 (34) 196 (35)




Not Ambulatory 234 (41) 228 (40)
Ambulatory 331 (59) 336 (60)
Other bone metastases 0.99
No 229 (41) 229 (41)
Yes 336 (59) 335 (59)
Visceral metastases 0.29
No 319 (56) 347 (62)
Yes 246 (44) 217 (38)
Interval from cancer
diagnosis to RT of MSCC
0.67
≤ 15 months 290 (51) 302 (54)




1-7 days 175 (31) 193 (34)
8-14 days 140 (25) 150 (27)
> 14 days 250 (44) 221 (39)
Table 1 Patient characteristics of the test group and the
validation group (Continued)
Radiation regimen 0.99
1 × 8 Gy 96 (17) 95 (17)
5 × 4 Gy 154 (27) 157 (28)
10 × 3 Gy 151 (27) 153 (27)
15 × 2.5 Gy 64 (11) 67 (12)
20 × 2 Gy 100 (18) 92 (16)
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square test). Each of the groups A to D of the validation
group was compared to each of the corresponding groups
A to D of the test group with respect to the ambulatory
rates at 1 month following RT. The p-values were p = 0.94
for groups A, p = 0.67 for groups B, p = 0.89 for groups C,
and p = 0.96 for groups D, respectively.
Discussion
Personalized treatment has gained importance in pallia-
tive oncology and radiation oncology during recent years
including prognostic scores [10,11]. A particular focus
has been placed on elderly patients usually defined as
65 years or older, since the proportion of this group of
patients in oncology has grown considerably [5,6]. About
70% of all cancer deaths occur in this age group [12].
The course of the cancer disease in elderly patients is
often different from that in younger patients. Moreover,
elderly patients may not tolerate or withstand aggressive
treatment approaches. Therefore, an over-treatment should
be avoided particularly in a palliative situation such as
MSCC. Since the mean age of the population in Western
countries is increasing, a patient’s performance status and
comorbidity must be taken into account in addition to the
numeric age. Patients older than 65 years who have a very
good performance status and little comorbidity may be
treated more aggressively like younger patients.
The majority of MSCC patients are treated with RT
alone. However, a small randomized trial of 101 patients
revealed that selected patients benefit from upfront de-
compressive surgery in addition to RT [1]. Since this study
was published in 2005, decompressive surgery has seen a
“boom” in some countries, particularly in Germany. How-
ever, spinal surgery entails significant risks such as wound
infections requiring a second surgery, extensive bleeding,
postoperative pneumonia, and pulmonary embolism, which
occur in more than 10% of the patients [1-4]. Therefore,
spinal surgery may be omitted, if reasonably possible. This
may be particularly true for elderly patients who have a
higher risk of experiencing surgery or anesthesia related
complications. In general, surgery for MSCC should be
proposed for selected patients, i.e. if there are diagnostic
doubts, if stabilization of the vertebral column is required,
Table 2 Test group: Ambulatory rates 1 month following






65-70 years (n = 230) 70 7
71-80 years (n = 266) 65 7
≥ 81 years (n = 69) 48 0.004 5
Gender
Female (n = 197) 73
Male (n = 368) 61 0.15
Type of primary tumor
Breast cancer (n = 89) 85 9
Prostate cancer (n = 150) 61 6
Myeloma/lymphoma (n = 51) 88 9
Lung cancer (n = 112) 66 7
Cancer of unknown primary
(n = 44)
36 4
Renal cell carcinoma (n = 34) 68 7
Colorectal cancer (n = 28) 39 4
Other tumors (n = 57) 54 0.002 5
Number of involved
vertebrae
1-2 (n = 235) 70
3-4 (n = 191) 64
≥ 5 (n = 139) 58 0.28
Ambulatory status prior
to RT
Not Ambulatory (n = 234) 24 2
Ambulatory (n = 331) 94 <0.001 9
Other bone metastases
No (n = 229) 72
Yes (n = 336) 60 0.64
Visceral metastases
No (n = 319) 74 7
Yes (n = 246) 53 0.017 5
Interval from cancer
diagnosis to RT of MSCC
≤ 15 months (n = 290) 58
> 15 months (n = 275) 73 0.18
Time developing motor
deficits
1-7 days (n = 175) 30 3
8-14 days (n = 140) 70 7
> 14 days (n = 250) 87 <0.001 9
Table 2 Test group: Ambulatory rates 1 month following
RT and the corresponding scoring points (Continued)
Radiation regimen
1 × 8 Gy (n = 96) 68
5 × 4 Gy (n = 154) 60
10 × 3 Gy (n = 151) 60
15 × 2.5 Gy (n = 64) 66
20 × 2 Gy (n = 100) 77 0.71
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deterioration of motor function during RT, after previous
longer-course RT, or if collapse of the vertebral body
causes bone impingement on the spinal cord or the nerve
roots. According to the study of Patchell et al., decom-
pressive surgery provides also benefit for patients with a
relatively good performance status and a relatively survival
prognosis [1]. If decompressive surgery is administered, it
should include stabilization of the involved vertebra; a
simple laminectomy has to be avoided [1-4]. Decom-
pressive surgery should not be used in patients with a
Karnofsky performance score of <70, an estimated survival
time of less than three months, involvement of more than
one spinal segment and very radiosensitive tumors such as
myeloma, lymphoma and germ cell tumors [1].
In the present study, or scoring system has been devel-
oped to help estimate the probability for elderly patients
to be ambulatory following RT alone for MSCC. There is
a lack of data regarding post-RT ambulatory status in
elderly patients developing MSCC, which was not evalu-
ated in our previous matched-pair analysis comparing
surgery plus RT and RT alone [4]. In the multivariate
analysis of the present study, five prognostic factors were
significantly associated with post-RT ambulatory status.
These factors were age, type of primary tumor, pre-RT
ambulatory status, visceral metastases, and the time
developing motor deficits.
In contrast to these five factors, the radiation regimen
was not associated with post-radiotherapy ambulatory
status. This finding agrees with previous studies. In two
randomized trials from Italy, 1×8 Gy was as effective as
2×8 Gy or a split-course regimen (3×5 Gy plus another
5×3 Gy after a week rest) [8,9]. Furthermore, in a pro-
spective study and a large retrospective study from
Germany, post-treatment functional outcome was simi-
lar after short-course RT such as 1×8 Gy and 5×4 Gy
when compared to longer-course RT programs such as
10×3 Gy, 15×2.5 Gy and 20×2 Gy [7,13,14]. In another
prospective study, 10×3 Gy and 20×2 Gy resulted in
similar functional outcomes [15].
Six years ago, we presented an ambulatory score based






19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 41
%
points
Figure 1 Test group: the total scores (19 to 41 points) in relation to the ambulatory rate at 1 month following RT (in%). Four prognostic
groups were designed: group A (19-25 points, red columns), group B (26-30 points, green columns), group C (31-34 points, blue columns), and
group D (35-41 points, orange columns).
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cancer and RT of MSCC was an independent prognostic
factor, but did not play a prognostic role in elderly patients
in the current study. This finding supports the concept
that elderly patients differ from younger patients and the
need for a separate score for the elderly patients.
In the present study, four prognostic groups were de-
fined. The ambulatory rates at 1 month following RT were
quite divergent ranging from only 5% to 98%. In addition,
the 6-month survival rates of the four groups differed
considerably ranging from 11% to 76%. Patients of group
A (19-25 points) had both a very low post-RT ambulatory
probability and a very poor survival prognosis. RT alone is
not successful regarding the functional outcome. These
results may be improved with decompressive surgery.
However, considering the poor expected survival, surgery
may not be a valuable addition. This is supported by the
fact that patients with a survival prognosis of less than
three months were not included in the randomized
trial of Patchell et al. [1]. Also in patients of group B (26-
30 points) and group C (31-34 points), the results of RT
alone are not optimal and may be improved with the
addition of decompressive surgery. Such an approach
appears more reasonable for these two groups, since the
survival prognoses are better than for group A patients.
Patients of group D (35-41 points) showed very good
results after RT alone with 98% of patients being ambula-
tory and 76% of patients living 6 months or longer. It may
be questioned whether these patients do need additional
surgery? In the current study, the ambulatory rates of
group D patients were 99%, 99% and 79% after 3 months,
6 months and 12 months, respectively, following RT.
These findings suggest that one may not need to perform
additional surgery in group D patients. However, the
data included in the current study were retrospectively
evaluated.
For validation of this new score, the four prognostic
groups A-D of the test group were each compared to the
corresponding groups A-D of the validation group. The
post-RT ambulatory rates of the four groups of the valid-
ation group were very similar to post-RT ambulatory ratesof the four groups of the test group. This finding demon-
strates that the score is valid and reproducible.
Conclusions
Patients achieving 19-25 points (group A) had both poor
functional outcomes and poor survival. Therefore, these
patients may be considered for best supportive care or
single-fraction RT if the patients experience pain. Patients
with 26-34 points (groups B and C) may benefit from add-
itional surgery, since the functional results of RT alone are
not optimal and the patients live longer than those of
group A. Patients achieving ≥35 points (group D) had very
good results after RT alone. Thus, the group D patients
may not require surgery. These findings should ideally be
re-evaluated in a prospective study.
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